Loading...
Loading...
AMLX| Name | Value |
|---|---|
| Revenues | 102.7M |
| Cost of Revenue | 5.2M |
| Gross Profit | 97.5M |
| Operating Expense | 78.8M |
| Operating I/L | 18.7M |
| Other Income/Expense | 3.7M |
| Interest Income | 4.2M |
| Pretax | 22.4M |
| Income Tax Expense | 1.5M |
| Net Income/Loss | 20.9M |
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their primary product in the pipeline is AMX0035, a dual UPR-Bax apoptosis inhibitor designed for the treatment of ALS. The company also aims to expand the application of AMX0035 to other neurodegenerative diseases, positioning itself as a leader in addressing these challenging medical conditions.
